The study will analyse Bryostatin-1 in the absence of Namenda for six-months. Credit: Mikael Häggström, M.D.

Biopharma company Neurotrope has dosed the first patient in its long-term Phase II trial of lead therapeutic candidate Bryostatin-1 to treat Alzheimer’s disease (AD).

Backed by a $2.7m grant, the trial plans to enrol around 100 patients and will be conducted in collaboration with the National Institutes of Health (NIH).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study will analyse Bryostatin-1 in the absence of Namenda (memantine) for six months including two 11-week dosing cycles.

Participants will include AD patients with pre-specified moderately severe and moderate disease, including those who showed evidence of benefit in the previous study.

The study will also assess sustained cognitive benefit as measured by the Severe Impairment Battery (SIB) score, a measure of cognitive function in advanced dementia patients.

Neurotrope president and chief scientific officer Dr Daniel Alkon said: “After reviewing data from previous trials of Bryostatin-1 with both key opinion leaders and the NIH, we determined that a study to evaluate its long-term therapeutic effects in the absence of Namenda in patients with AD was a priority.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This study is backed by Phase II clinical data from a pilot trial, which assessed Bryostatin-1 in the absence of Namenda for 11 weeks.

Results showed that a 20mcg dose of the drug was well tolerated and demonstrated early signals of cognitive benefit, which included improvement in SIB score by 5.0 points as compared to baseline in the Moderate Stratum cohort in the non-Namenda group.

This SIB score improvement was consistent throughout the treatment period and persisted for four weeks even after treatment ended.

A second pilot trial using the same treatment protocol showed a similar SIB improvement.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now